Aytu BioPharma, Inc. (AYTU)
NASDAQ: AYTU · Real-Time Price · USD
2.190
+0.290 (15.26%)
At close: Oct 6, 2025, 4:00 PM EDT
2.240
+0.050 (2.28%)
Pre-market: Oct 7, 2025, 4:12 AM EDT
Aytu BioPharma Employees
As of June 30, 2025, Aytu BioPharma had 83 total employees, including 82 full-time and 1 part-time employees. The number of employees decreased by 16 or -16.16% compared to the previous year.
Employees
83
Change (1Y)
-16
Growth (1Y)
-16.16%
Revenue / Employee
$650,804
Profits / Employee
-$132,961
Market Cap
21.71M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Jun 30, 2025 | 83 | -16 | -16.16% |
| Jun 30, 2024 | 99 | -51 | -34.00% |
| Jun 30, 2023 | 150 | -14 | -8.54% |
| Jun 30, 2022 | 164 | -11 | -6.29% |
| Jun 30, 2021 | 175 | 100 | 133.33% |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
AYTU News
- 12 days ago - Aytu BioPharma to Present at Upcoming September 2025 Conferences - Accesswire
- 13 days ago - Aytu BioPharma, Inc. (AYTU) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 13 days ago - Aytu BioPharma Reports Fiscal 2025 Full Year and Fourth Quarter Operational and Financial Results and Outlines Commercial Launch Plans for EXXUA(TM) - Accesswire
- 20 days ago - Aytu BioPharma to Report Fiscal 2025 Full Year and Fourth Quarter Operational and Financial Results on September 23, 2025 - Accesswire
- 3 months ago - Aytu BioPharma Appoints Dr. Gerwin Westfield as Senior Vice President of Scientific Affairs to Support Commercialization of EXXUA(TM) - Accesswire
- 3 months ago - Aytu BioPharma Expands and Extends Lending Agreement with Eclipse Following Agreement to Commercialize First-in-Class Antidepressant EXXUA(TM) - Accesswire
- 4 months ago - Aytu BioPharma Announces Closing of Upsized At the Market Public Offering of Common Stock with Full Exercise of Overallotment and Conference Call to Discuss First-in-Class Antidepressant EXXUA(TM) Opportunity and Commercialization Plan - Accesswire
- 4 months ago - Aytu BioPharma Announces At the Market Pricing of $14.4 Million Upsized Public Offering of Common Stock - Accesswire